• 高级搜索
  • 进入期刊界搜索引擎>>
刘新桥.芪苈强心胶囊对冠心病心力衰竭患者氧化应激及外周血miRNA-21和miRNA-145表达的影响[J].中国动脉硬化杂志,2020,(8):697~701
芪苈强心胶囊对冠心病心力衰竭患者氧化应激及外周血miRNA-21和miRNA-145表达的影响
Effects of Qiliqiangxin capsule on oxidative stress and expressions of miRNA-21 and miRNA-145 in peripheral blood of patients with coronary heart disease and heart failure
投稿时间:2019-06-13  修订日期:2019-08-06
DOI:
中文关键词:  芪苈强心胶囊  冠心病  心力衰竭  脑钠肽  氧化应激  miRNA-21  miRNA-145
英文关键词:Qiliqiangxin capsule  coronary heart disease  heart failure  brain natriuretic peptide  oxidative stress  miRNA-21  miRNA-145
基金项目:
作者单位E-mail
刘新桥 首都医科大学附属北京安贞医院中医理疗科,北京市 100029 e-mail为1334782741@qq.com 
摘要点击次数: 18
全文下载次数: 3
中文摘要:
      目的 探讨芪苈强心胶囊对冠心病心力衰竭患者氧化应激及外周血miRNA-21(miR-21)和miRNA-145(miR-145)表达的影响。方法 选择2017年1月至2018年12月期间本院收治的冠心病心力衰竭患者86例作为研究对象,采用随机数字表法随机分为对照组43例与观察组43例。对照组采取常规治疗;观察组在对照组基础上结合芪苈强心胶囊治疗。2组疗程均为4周。比较2组治疗疗效、治疗前后心功能、脑钠肽(BNP)、氧化应激指标及外周血miR-21和miR-145表达变化。结果 观察组总有效率高于对照组(93.02%比72.09%,P<0.05)。观察组治疗后左心室舒张期末内径和左心室收缩期末内径低于对照组,而左心室射血分数高于对照组(P<0.05)。2组治疗后血浆BNP水平较治疗前降低(P<0.05);治疗后观察组血浆BNP水平明显低于对照组(P<0.05)。2组治疗后丙二醛(MDA)水平较治疗前降低,而超氧化物歧化酶(SOD)水平较治疗前升高(P<0.05);治疗后观察组MDA水平低于对照组,而SOD水平高于对照组(P<0.05)。2组治疗后外周血miR-21和miR-145表达较治疗前降低(P<0.05);治疗后观察组外周血miR-21和miR-145表达低于对照组(P<0.05)。随访3~10个月,观察组再住院率及病死率均较低,再住院率明显低于对照组(P<0.05)。结论 芪苈强心胶囊对冠心病心力衰竭患者疗效良好,可降低血浆BNP水平,降低氧化应激损伤,及下调外周血miR-21和miR-145表达。
英文摘要:
      Aim To investigate the effects of Qiliqiangxin capsule on oxidative stress and expressions of miRNA-21 (miR-21) and miRNA-145 (miR-145) in peripheral blood of patients with coronary heart disease and heart failure.Methods The 86 patients with coronary heart disease and heart failure admitted to our hospital from January 2017 to December 2018 were selected as the study subjects. They were randomly divided into control group (43 cases) and observation group (43 cases) by random number table method. The patients in the control group were treated with routine therapy, while the patients in the observation group were treated with Qiliqiangxin capsule on the basis of the control group. Both groups were treated for 4 weeks. The therapeutic effect, cardiac function, BNP, oxidative stress indexes and the expressions of miR-21 and miR-145 in peripheral blood before and after treatment were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group (93.02% vs 72.09%, P<0.05). After treatment, the left ventricular end-diastolic diameter and left ventricular end-systolic diameter in the observation group were lower than those in the control group, while the left ventricular ejection fraction was higher than that in the control group (P<0.05). The level of BNP in the two groups after treatment was lower than that before treatment (P<0.05); After treatment, the level of BNP in the observation group was significantly lower than that in the control group (P<0.05). The level of malondialdehyde (MDA) in the two groups after treatment was lower than that before treatment, while the level of superoxide dismutase (SOD) was higher than that before treatment (P<0.05); After treatment, the MDA level of the observation group was lower than that of the control group, while the SOD level was higher than that of the control group (P<0.05). The expressions of miR-21 and miR-145 in peripheral blood of the two groups after treatment was lower than that before treatment (P<0.05); After treatment, the expressions of miR-21 and miR-145 in the peripheral blood of the observation group was lower than that of the control group (P<0.05). After 3-10 months follow-up, the rates of readmission and mortality in the observation group were lower, and its readmission rate was significantly lower than that in the control group (P<0.05). Conclusion Qiliqiangxin capsule has a good therapeutic effect on patients with coronary heart disease and heart failure, and it can reduce the level of plasma BNP, oxidative stress injury and the expressions of miR-21 and miR-145 in peripheral blood.
查看全文  查看/发表评论  下载PDF阅读器
关闭




您是本站第 9655781位访问者
版权所有:中国动脉硬化杂志  湘ICP备11008367号
主管单位:中国科学技术协会  主办单位:中国病理生理学会、南华大学
电话:0734-8160765  传真:0734-8160523  E-mail:dmzzbjb@163.net  网址:www.dmzzbjb.net
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win);}&et=970261AF74811A5D2FE018A0344E49D65F5FE166FFDA8D5B9AAD56CB6AA39C7EFE969B71B7096B05CA233D60D88CB4FC5B8D3E274F7F7567BF14968F88F77FA3DCF2489D6D3DD49CF5522588BFCA6CACCEF3E37DA9CC2AACDEA4C678F324EF849CB1E8E72D9844B7C3C3EA9FE5A71E958A2979D0E7100E29668BFFA9F91D9E7E513EB36415FE6A908F629A2D114FAC7EF7881FF3D7314C45F002F085A70F2CD0D28ED5AFA04D281C869DC38B8092A373&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=AD36F34DDC3BA7B0&jid=&yid=0D1D160AB8016934&aid=&vid=&iid=5D311CA918CA9A03&sid=780091CB32840698&eid=80BBC722D530DB8D&fileno=20200810&flag=1&is_more=0">var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC";var my_cid="AD36F34DDC3BA7B0";var my_jid="";var my_yid="0D1D160AB8016934";var my_aid="";